Search Results | Litt's Drug Eruption and Reaction Database

The most comprehensive database on adverse drug reactions for our profession.David Adams MD

Log in

Menu

Login

Home
About About
Alerts
Litt’s App
Contact Us
Help
Subscribe Subscribe
- Individual Subscription
- Institutional Subscription

Drugs belonging to restart save

class – Antiretroviral – 31 items found

Search:

show all
0–9
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Adefovir Compare:

Amprenavir Compare:

Atazanavir Compare:

Bictegravir/Emtricitabine/Tenofovir Alafenamide Compare:

Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide Compare:

Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil Compare:

Darunavir Compare:

Delavirdine Compare:

Didanosine Compare:

Dolutegravir Compare:

Efavirenz Compare:

Emtricitabine Compare:

Enfuvirtide Compare:

Fosamprenavir Compare:

Fostemsavir Compare:

Hydroxyurea Compare:

Ibalizumab Compare:

Indinavir Compare:

Lamivudine Compare:

Lopinavir Compare:

Loading more results

No more results to show

Adverse reactions attributed to entire drug class 'Antiretroviral'

Please login to view adverse reactions.

(2025): Majumdar N+, Funct Integr Genomics 25(1), 81 [REVIEW]

Urolithiasis / ureteral stones / urinary calculi

(2014): Izzedine H+, Clin Kidney J 7(2), 121-6 [REVIEW]

Hematological adverse effect

(2019): Oumar AA+, Int J Basic Clin Pharmacol 8(5), 83115%

Optic neuropathy

(2013): Wang MY+, J Neuroophthalmol 33(2), 172 [REVIEW]

Adverse effects / adverse reactions

(2019): Oumar AA+, Int J Basic Clin Pharmacol 8(5), 83142%
(2014): Lorio M+, J Int Assoc Provid AIDS Care 13(5), 4666%

Saved Searches Watched Drugs

Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere

With full access to drug profiles, reactions and linked PubMed abstracts through your smart phone! If you subscribe via your institution and do not have a personal login you will need to register on the website to create a login for the app.

Help
Terms & Conditions
Privacy
Disclaimer
Contact us

© 2025 Taylor & Francis Group, LLC. All Rights Reserved.